{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:32:40Z","timestamp":1770971560559,"version":"3.50.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1097\/iae.0000000000000632","type":"journal-article","created":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T17:23:58Z","timestamp":1433438638000},"page":"2450-2456","source":"Crossref","is-referenced-by-count":57,"title":["INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA"],"prefix":"10.1097","volume":"35","author":[{"given":"Jose M.","family":"Ruiz-Moreno","sequence":"first","affiliation":[]},{"given":"Javier A.","family":"Montero","sequence":"additional","affiliation":[]},{"given":"Javier","family":"Araiz","sequence":"additional","affiliation":[]},{"given":"Luis","family":"Arias","sequence":"additional","affiliation":[]},{"given":"Alfredo","family":"Garc\u00eda-Layana","sequence":"additional","affiliation":[]},{"given":"Angela","family":"Carneiro","sequence":"additional","affiliation":[]},{"given":"Marta S.","family":"Figueroa","sequence":"additional","affiliation":[]},{"given":"Rufino","family":"Silva","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-3-20210130","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/IAE.0b013e3181c9691e","article-title":". Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results.","volume":"30","author":"Silva","year":"2010","journal-title":"Retina"},{"key":"R3-3-20210130","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/bjo.2005.066431","article-title":". Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia.","volume":"89","author":"Nguyen","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R4-3-20210130","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/bjo.2008.145391","article-title":". Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome.","volume":"93","author":"Ruiz-Moreno","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R5-3-20210130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bjo.2006.099887","article-title":". Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.","volume":"91","author":"Sakaguchi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R6-3-20210130","first-page":"308","article-title":". New drug VEGF Trap-EyeEyleaand its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia in Polish.","volume":"114","author":"Rejdak","year":"2012","journal-title":"Klin Oczna"},{"key":"R8-3-20210130","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/bjophthalmol-2012-301639","article-title":". Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia.","volume":"96","author":"Gharbiya","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R9-3-20210130","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/IAE.0b013e3182278bae","article-title":". Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia.","volume":"32","author":"Hayashi","year":"2012","journal-title":"Retina"},{"key":"R10-3-20210130","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jcjo.2011.12.009","article-title":"Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results.","volume":"47","author":"Peiretti","year":"2012","journal-title":"Can J Ophthalmol"},{"key":"R11-3-20210130","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/bjophthalmol-2012-302973","article-title":". Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome.","volume":"97","author":"Ruiz-Moreno","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R12-3-20210130","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/IAE.0b013e31817eda41","article-title":". Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization.","volume":"28","author":"Silva","year":"2008","journal-title":"Retina"},{"key":"R13-3-20210130","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/eye.2013.8","article-title":". Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study.","volume":"27","author":"Tufail","year":"2013","journal-title":"Eye (Lond)"},{"key":"R14-3-20210130","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/eye.2012.97","article-title":". Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.","volume":"26","author":"Lai","year":"2012","journal-title":"Eye (Lond)"},{"key":"R15-3-20210130","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":". Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"R16-3-20210130","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-0032-1328366","article-title":"Three years follow-up results of ranibizumab treatment for choroidal neovascularization secondary to pathologic myopia.","volume":"230","author":"Hefner","year":"2013","journal-title":"Klin Monbl Augenheilkd"},{"key":"R17-3-20210130","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1111\/j.1755-3768.2010.02070.x","article-title":". Three versus one intravitreal bevacizumab injections as initial protocol to treat myopic choroidal neovascularization.","volume":"90","author":"Ruiz-Moreno","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"R18-3-20210130","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/bjo.2009.166025","article-title":". Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation.","volume":"94","author":"Baba","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"R19-3-20210130","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.ophtha.2011.07.029","article-title":". Myopic choroidal neovascularization.","volume":"118","author":"Ruiz-Moreno","year":"2011","journal-title":"Ophthalmology"},{"key":"R20-3-20210130","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.ophtha.2013.03.006","article-title":". Intravitreal bevacizumab in myopic neovascular membranes: 24-months results.","volume":"120","author":"Ruiz-Moreno","year":"2013","journal-title":"Ophthalmology"},{"key":"R21-3-20210130","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/IAE.0b013e31827d260a","article-title":"Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia. Systematic review and metaanalysis.","volume":"33","author":"Wang","year":"2013","journal-title":"Retina"},{"key":"R22-3-20210130","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.preteyeres.2012.04.001","article-title":". Choroidal neovascularization in pathological myopia.","volume":"31","author":"Neelam","year":"2012","journal-title":"Prog Retin Eye Res"},{"key":"R23-3-20210130","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00417-006-0472-6","article-title":"Pegaptanib for myopic choroidal neovascularization in a young patient.","volume":"245","author":"Bennett","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R24-3-20210130","first-page":"387","article-title":"Anty-VEGF therapy in the treatment of myopic macular choroidal neovascularizationcases report in Polish.","volume":"110","author":"Figurska","year":"2008","journal-title":"Klin Oczna"},{"key":"R25-3-20210130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00417-008-0995-0","article-title":". Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.","volume":"247","author":"Konstantinidis","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R26-3-20210130","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IAE.0b013e31819ed6bd","article-title":". Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.","volume":"29","author":"Lai","year":"2009","journal-title":"Retina"},{"key":"R27-3-20210130","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.ophtha.2007.03.043","article-title":". Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.","volume":"114","author":"Chan","year":"2007","journal-title":"Ophthalmology"},{"key":"R28-3-20210130","first-page":"707","article-title":". Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.","volume":"27","author":"Hernandez-Rojas","year":"2007","journal-title":"Retina"},{"key":"R29-3-20210130","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/bjo.2007.130260","article-title":". Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results.","volume":"92","author":"Arias","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R30-3-20210130","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archopht.126.7.941","article-title":". Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration.","volume":"126","author":"Chang","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"R36-3-20210130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1471-2415-14-69","article-title":". Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study.","volume":"14","author":"Cha","year":"2014","journal-title":"BMC Ophthalmol"},{"key":"R39-3-20210130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000357290","article-title":". Progression of myopic maculopathy after treatment of choroidal neovascularization.","volume":"231","author":"Farinha","year":"2014","journal-title":"Ophthalmologica"},{"key":"R40-3-20210130","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1097\/IAE.0000000000000201","article-title":". Long-term functional and morphologic retinal changes after ranibizumab and photodynamic therapy in myopic choroidal neovascularization.","volume":"34","author":"Parravano","year":"2014","journal-title":"Retina"},{"key":"R41-3-20210130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s10384-014-0363-z","article-title":". Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab.","volume":"59","author":"Cohen","year":"2015","journal-title":"Jpn J Ophthalmol"},{"key":"R42-3-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00417-012-2022-8","article-title":". Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization.","volume":"251","author":"Oishi","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R43-3-20210130","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00417-011-1921-4","article-title":". Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization.","volume":"250","author":"Uemoto","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R45-3-20210130","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0161-6420(03)00461-5","article-title":". Myopic choroidal neovascularization: a 10-year follow-up.","volume":"110","author":"Yoshida","year":"2003","journal-title":"Ophthalmology"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000000632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:10:11Z","timestamp":1620954611000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201512000-00003"}},"subtitle":["Six Years Outcome"],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000000632","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}